Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials

2025/02/28 by Charlotte-Paige Rolle, José Ramón Arribas, Roberto Ortiz +6 · 2 voices
Medicine · Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · #HIV/AIDS drug development and treatment #HIV Research and Treatment #Biochemical and Molecular Research

paper · pdf · doi:10.1093/ofid/ofaf135

Abstract

Abstract Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (≥500 000 copies/mL). Clinical Trials Registration. NCT02831673/NCT02831764; NCT03945981.

Discussions

• Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials ✅ Just Accepted ⭐ Editor's Choice #IDSky [bsky, 6 points, 0 comments]
• doi.org/10.1093/ofid... [bsky, 1 points, 0 comments]

Related

• Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial
• Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
• Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
• DOLCE: Sweet Success for Dolutegravir/Lamivudine?
• A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study